Can a simple blood test tell who needs more cancer treatment?
NCT ID NCT06287814
First seen Jun 25, 2026 · Last updated Aug 19, 2026 · Updated 3 times
Summary
This study is testing whether a blood test that looks for cancer DNA (called a liquid biopsy) can find leftover cancer cells after surgery in people with stage III colorectal cancer. The goal is to see if this test can help doctors decide who needs additional treatment and who can safely avoid it. The study will follow 70 patients for three years to see how well the test predicts cancer return.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- liquid biopsy (ctDNA blood test)
- What this could lead to
- If successful, this could help doctors know which patients need more treatment after surgery and which do not, reducing unnecessary side effects.
- What could go wrong
- This is an early-stage observational study with only 70 participants. The tests may not be accurate enough to guide treatment decisions yet.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 70 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2024
- Expected to finish
-
Oct 2033
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
PART All patients with resected stage I to III CRC PART II Patients with stage III CRC with adjuvant chemotherapy
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
FRENCH.MRD.CRC PART I Inclusion criteria * Colon or rectal cancer, clinical tumor stage I-III. * Patient 18 years or older. * Scheduled for curative intent resection surgery (including "compromised" curative resections). Exclusion criteria * Hereditary colorectal cancer linked to familial colonic polyposis or Lynch syndrome. * Verified distant metastases. * Malignant colorectal polyps diagnosed after polypectomy. * Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study. * Pregnant or nursing woman, or in childbearing age and not willing to use contraception * Protected and vulnerable adult * Not covered by Health insurance * Patient unable to understand and sign written informed consent. FRENCH.MRD.CRC PART II Inclusion criteria * Participation in FRENCH.MRD.CRC part 1 - SURGERY * Colorectal cancer, UICC stage III * Has received curative-intent resection and is a candidate for adjuvant chemotherapy (3- or 6-months regime) Exclusion criteria * Inflammatory bowel disease (Crohn's disease or ulcerative colitis) related colon cancer * Not treated with adjuvant chemotherapy despite indication (incomplete treatment not included) * Treated with neoadjuvant chemo-radiation therapy * Synchronous colorectal and non-colorectal cancer diagnosed per operative (except skin cancer other than melanoma) * Other cancers (excluding colorectal cancer or skin cancer other than melanoma) within 3 years from eligibility screening * Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU de Montpellier
RECRUITINGMontpellier, Hérault, 34295, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a lab test tell which chemo works for colon cancer?
- Can MRI and computer models predict how well cancer drugs reach tumors?
- Watch and wait: could immunotherapy let some GI cancer patients avoid surgery?
- Gut bacteria may hold clues to why some cancer treatments work better
- Burning the edges: a new way to stop colon polyps from coming back
- Missed Follow-Up colonoscopies: do they raise the risk of advanced growths?